Literature DB >> 7028376

"Atypical" mycobacterioses.

D Y Rosenzweig.   

Abstract

Infections due to atypical mycobacteria appear to be growing in importance. In part, this may be due to enhanced recognition as tuberculosis recedes and laboratory identification improves. In a larger part, however, it is due to real increase in the incidence of infections and disease and to our appreciation of a wide spectrum of manifestations of common problems as in pulmonary disease due to MAIS, as well as newer diseases in unexpected places such as infected prostheses due to M. fortuitum complex. These organisms generally conform to a role as opportunists. The average case occurs when some type of host compromise is present and the disease course is chronic and indolent. However, otherwise healthy host can be affected and severe and progressive diseases also do occur. These mycobacteria are all more resistant to antituberculosis chemotherapy than is M. tuberculosis. Effective therapy has been found for some, especially M. kansaii. For most others, more predictable, effective, and safe therapy is greatly needed.

Entities:  

Mesh:

Year:  1980        PMID: 7028376

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  4 in total

1.  Short-course chemotherapy for mycobacteriosis kansasii?

Authors:  D E Schraufnagel; J A Leech; M N Schraufnagel; B Pollak
Journal:  Can Med Assoc J       Date:  1984-01-01       Impact factor: 8.262

2.  Mycobacterium avium-intracellulare contamination of mammalian cell cultures.

Authors:  I H Lelong-Rebel; Y Piemont; M Fabre; G Rebel
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-10-15       Impact factor: 2.416

3.  Essentials of tuberculosis control for the practising physician. Tuberculosis Committee, Canadian Thoracic Society.

Authors: 
Journal:  CMAJ       Date:  1994-05-15       Impact factor: 8.262

4.  Characterization of Proinflammatory Responses and Innate Signaling Activation in Macrophages Infected with Mycobacterium scrofulaceum.

Authors:  Ki-Hye Kim; Tae-Sung Kim; Joy G Lee; Jeong-Kyu Park; Miso Yang; Jin-Man Kim; Eun-Kyeong Jo; Jae-Min Yuk
Journal:  Immune Netw       Date:  2014-12-22       Impact factor: 6.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.